Background {#Sec1}
==========

Heart failure (HF) is a major public health problem with increasing prevalence worldwide \[[@CR1]\]. Once established, worsening heart failure is frequent and associated with significantly diminished quality of life, recurrent hospital admissions and direct impacts in healthcare costs \[[@CR2]\]. The estimated prevalence of HF is 1 to 2% of the adult population in developed countries \[[@CR3]\]. In Brazil, the HF prevalence is 2 million patients and its incidence is 240,000 new cases per year \[[@CR4]\].

Despite the fact that most data on outcomes in patients with HF come from North America and Europe \[[@CR5]\]; recently, several studies reported the risk factor prevalence and mortality predictors variation among races \[[@CR6]--[@CR8]\]. Brazil has the largest universal health system in the world; in addition, it is characterized by intense racial admixture, social inequalities and cultural traditions that may impact the natural history of HF. Finally, comprehensive epidemiological, clinical and therapeutic data on chronic HF are still lacking and making the definition of population strategies for disease treatment and prevention at the least difficult to forecast.

In this scenario, we have conducted the GENIUS-HF (Genetic and ElectroNic medIcal records to predict oUtcomeS in Heart Failure patients) study, a Brazilian cohort that aims to contribute with the characterization of risk predictors and the impact of multimorbidity related to chronic HF \[[@CR9]\].

The purpose of this study was to describe baseline characteristics, one-year outcomes and predictors of mortality and hospitalization of chronic heart failure patients.

Methods {#Sec2}
=======

The cohort {#Sec3}
----------

GENIUS-HF (Genetic and ElectroNic medIcal records to predict oUtcomeS in Heart Failure patients) is an observational, prospective, single-center cohort started in 2012 and still ongoing. Invited individuals were patients with chronic systolic heart failure sequentially seen at the SPA outpatient clinic at the Heart Institute, University of São Paulo Medical School (InCor - HCFMUSP). The SPA clinic is an outpatient clinic responsible for triaging patients from primary and secondary care sites to a tertiary care site. The rationale and design for this study have been previously published \[[@CR9]\]. Since 2012, 700 patients were included from 2314 individuals screened at the outpatient clinic due to HF symptoms (Fig. [1](#Fig1){ref-type="fig"}: Flowchart). Enrolled patients were submitted to a clinical baseline evaluation, complementary exams (echocardiography, cardiograph impedance) and biochemical tests, which included blood, urine and biobanking samples for future analysis. After enrollment, patients would be taken care at different units of the public medical system and study investigators did not influence any of the medical decisions involving participants. Follow-up was made thru phone interview every six-months. Fig. 1Flowchart. Reasons for patients exclusion were: Ejection fraction \> = 50% or echocardiogram with a date exceeding 2 years of acquisition (316 patients); Patients without echocardiogram at the time of the invitation - clinical diagnosis of HF only (587 patients); Age \> 80 years at the time of inclusion (84 patients); Patient without telephone contact for recruitment (334 patients); Refusal of the eligible patient or responsible person to participate (230 patients); Death before the invitation for inclusion (63 patients)

Ethical aspects {#Sec4}
---------------

The study protocol was approved by the Ethics Committee for Medical Research on Human Beings of the Clinical Hospital from University of São Paulo Medical School (Protocol number SDC 2368/03/162). Signed informed consent was obtained from all participants. This study was retrospectively registered at clinicaltrials.gov (NTC02043431) in January 23, 2014.

Eligibility criteria {#Sec5}
--------------------

Patients between 18 and 80 years old and with systolic heart failure diagnosis from different etiologies were eligible for enrollment in the cohort. The left ventricular ejection fraction ≤50% was confirmed on two-dimensional transthoracic Doppler echocardiography performed in the past 2 years before enrollment. The diagnosis of heart failure was made according to previously published criteria \[[@CR10]\]. To define the appropriate etiology of cardiomyopathy, the authors followed previous guidelines \[[@CR11], [@CR12]\]. Patients with impaired cognition due to advanced dementia or severe psychiatric disorder, without telephone access or that refused to participate in follow-up procedures were not eligible.

Studied variables {#Sec6}
-----------------

Data collection included demographic variables (sex, ethnicity, age) duration of symptoms, etiology of heart failure, comorbidities, smoking status, body mass index, heart rate, blood pressure, cardiac rhythm, and cardiac dimensions, left ventricle ejection fraction, medication use and clinical outcomes.

Outcomes {#Sec7}
--------

Patients included have been submitted to telephone follow-up in 6 and 12-months to assess cardiovascular outcomes: all-cause mortality, hospitalization and heart transplantation. Regarding the 67 patients that had only the first telephone contact, we consider the events occurred in this period of follow up. All events were adjudicated by study investigators.

Statistical analysis {#Sec8}
--------------------

Means and SD were calculated for continuous variables, counts and percentages for categorical.

variables, and median (IQR) for BNP due to non-normality. We performed logarithmic.

transformation of BNP in order to normalize the sample data for analysis. Baseline characteristics were compared using One-way ANOVA followed by Dunnet for continuous variables and Chi-square test for categorical variables. The prognostic value was tested by univariate and multivariate Cox proportional hazard analysis. The multivariate analysis was constructed with the significant variables in the bivariate model. A value of *p* \< 0.05 was considered statistically significant for all comparisons. These analyses were performed using a statistical software package e (SPSS ver. 20.0, IBM, Armonk, NY, USA).

Results {#Sec9}
-------

Since 2012 we screened 2314 consecutive patients for eligibility and enrolled 700 participants. This paper describes the prognosis value of clinical baseline and laboratorial characteristics of the sample.

Five individuals have withdrawn the informed consent and were excluded from the study. Among 695 participants, 3 (0.4%) individuals did not respond to any follow-up contact and 67 (9.6%) have only the 6-month contact (Fig. [1](#Fig1){ref-type="fig"}, flowchart).

The overall one-year mortality was 6.8% (47 patients) and the composite outcome of death or hospitalization was 17.7% (123 patients). Seven patients (1%) have been submitted to heart transplantation during one year of enrollment.

The baseline characteristics of the individuals (Table [1](#Tab1){ref-type="table"}) showed a mean age of 55.4 years old and male gender predominance (67.6%) as well as self-referred mixed race (49.6%). The main comorbidities were dyslipidemias (66.5%) followed by hypertension (64.5%), diabetes (29.5%) and chronic kidney disease (26.9%). In this sample, 9.2% were previous or current smokers. Table 1Baseline demographic and clinical characteristicsVariableTotal (*n* = 695)Age (years)55.4 + 12.2Gender (Male) n(%)470 (67.6)*Race n(%)* Asian7 (1.0) Black107 (15.4) Mixed345 (49.6) White236 (34.0)Hypertension n(%)448 (64.5)Diabetes n(%)205 (29.5)Dyslipidemias n(%)462 (66.5)Smoking n(%)64 (9.2)Chronic Renal Failure n(%)187 (26.9)COPD n(%)49 (0.07)CABG n(%)34 (0.04)PCI n(%)50 (0.07)HIV n(%)2 (0.003)*Heart Failure Class n(%)* NYHA I130 (18.7) NYHA II433 (62.3) NYHA III127 (18.3) NYHA IV5 (0.7)Ejection Fraction (%)32.0 + 8.6LVDD n(%)64.1 + 8.3*Heart failure etiology n(%)* hypertensive181 (26.0) ischemic152 (21.9) chagasic118 (17.0) idiopathic108 (19.6)  other136 (8.6) Weight (Kg)75.8 + 19.1 Body mass index (kg/m2)27.9 + 6.0 Heart rate (bpm)71.2 + 14.3 Systolic blood pressure (mmHg)123.5 + 23.8 Diastolic blood pressure (mmHg)76.2 + 14.6 Dyspnea n(%)599 (86.2) Orthopnea n(%)263 (37.8) Paroxysmal nocturnal dyspnea n(%)150 (21,6) Jugular venous distension n(%)250 (36.0) Pulmonary rales n(%)52 (7.5) Peripheral edema n(%)127 (18.3) Third heart sound n(%)50 (7.2) Hepatojugular reflux n(%)71 (10.2) Capillary filling time (3--5 s) n(%)19 (2.7) Ascitis n(%)18 (2.6) Hepatomegaly n(%)79 (11.4) Creatinine (mg/dL)1.27 + 0.77 Blood urea nitrogen (mg/dL)49.3 + 23.7 CKD-EPI (μmol/L)68.2 + 22.7 Sodium (mg/dL)139.3 + 2.72 Potassium (mg/dL)4.8 + 0.6 Hemoglobin (mg/dL)13.9 + 1.7 Hematocrit (%)43.0 + 5.2 Blood glucose fasting (mg/dL)113.6 + 51.2 Glycated hemoglobin (%)6.3 + 0.7 High sensitive troponin (ng/dL)0.040 + 0.062 BNP (pg/mL)149 (54--355)*Medication in use n (%)* Beta blocker673 (96.8) ACE inhibitor427 (61.4) ARB207 (30.0) Nitrate98 (14.1) Hydralazine116 (16.7) Diuretic631 (90.8) Digital165 (23.7) Lipid lowering332 (47.8)Continuous variables are expressed as mean ± SDCategorical variables are presented as absolute number and percentage \[n (%)\]BNP was expressed as median (interquartile range) due to non-normality*COPD* Chronic Obstructive Pulmonary Disease, *CABG* Coronary Artery Bypass Grafting, *PCI* Percutaneous Coronary Intervention, *HIV* Human Immunodeficiency Virus, *NYHA* New York Heart Association, *LVDD* left ventricular end diastolic dimension, *CKD-EPI* Chronic Disease Epidemiology Collaboration, *BNP* brain natriuretic peptide, *ACEi* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blocker

Regarding heart failure etiology distribution, we observed a predominance of hypertensive (26.0%), ischemic (21.9%) and chagasic (17.0%) forms of cardiomyopathy. Most of the included individuals were in NYHA class I/II (81%) at enrollment.

Mean BMI (body mass index) was 27.9 kg/m2. Eighty six percent of the patients reported dyspnea as a symptom and jugular venous distension was the most observed clinical sign at examination (36% of the patients). Median BNP (brain natriuretic peptide) was 149 pg/mL (interquartile range: 54--355). Regarding medication, 96.8% of patients were in use of a beta-blocker; 91.1% used ACEi or ARB medication and 90.8% of the patients were in use of some diuretic at baseline.

Table [2](#Tab2){ref-type="table"} presents results for the Cox proportional hazards regression model estimated in the cohort using all pre-specified clinical and demographic characteristics. After multivariate adjustment, BUN (hazard ratio \[HR\] 1.017; 95% CI 1.008--1.027), Log BNP (hazard ratio \[HR\] 1.695; 95% CI 1.347--2.1134) and systolic blood pressure (hazard ratio \[HR\] 0.982; 95% CI 0.969--0.995) were independently associated with death within 1 year. Table 2Variables associated with all-cause mortality at 1 yearUnivariate analysisMultivariate analysisVariablesHR95% CIpHR95% CIpAge1.0261.001--1.0510.360Gender0.8840.642--1.2160.448Ejection fraction0.9510.917--0.987***0.007***1.0070.967--1.0490.736Hemoglobin0.8460.721--0.993***0.041***Sodium0.9560.859--1.0640.411BUN1.0241.017--1.032***\< 0.001***1.0171.008--1.027***\< 0.001***Log BNP2.0741.664--2.585***\< 0.001***1.6951.347--2.134***\< 0.001***Systolic blood pressure0.9720.958--0.986***\< 0.001***0.9820.969--0.995***0.008***High sensitive troponin22.7653.155--164.252***0.002***16.7170.960--291.2500.053*BUN* blood urea nitrogen, *Log BNP* brain natriuretic peptide logarithmicVariables which univariate analysis resulted in *p* \< 0.04 were included in a multivariate analysis

We have also analyzed the composite endpoint of death and hospitalization in 1 year (Table [3](#Tab3){ref-type="table"}). After multivariate adjustment, BUN (hazard ratio \[HR\] 1.008; 95% CI 1.001--1.015), Log BNP (hazard ratio \[HR\] 1.338; 95% CI 1.158--1.545), high sensitive troponin (hazard ratio \[HR\] 8.801; 95% CI 1.824--42.466) and age (hazard ratio \[HR\] 1.026; 95% CI 1.010--1.043) were associated with death and hospitalization within 1 year. Table 3Variables associated with hospitalization and all-cause mortality at 1 yearUnivariate analysisMultivariate analysisVariablesHR95% CIpHR95% CIpAge1.0361.020--1.053***\< 0.001***1.0261.010--1.043***0.001***Gender1.0040.688--1.4640.985Ejection fraction0.9750.954--0.996***0.020***0.9910.967--1.0150.443Hemoglobin0.8480.767--0.936***0.001***0.9170.825--1.0190.107Sodium0.9350.874--1.0010.055BUN1.0171.011--1.022***\< 0.001***1.0081.001--1.015***0.019***Log BNP1.5471.359--1.761***\< 0.001***1.3381.158--1.545***\< 0.001***Systolic blood pressure0.9910.983--0.999***0.024***0.9940.986--1.0020.129High sensitive troponin16.3984.368--61.562***\< 0.001***8.8011.824--42.466***0.007****BUN* blood urea nitrogen, *Log BNP* brain natriuretic peptide logarithmicVariables which univariate analysis resulted in p \< 0.04 were included in a multivariate analysis

In Fig. [2](#Fig2){ref-type="fig"}, Kaplan Meier curves compared all etiologies. Ischemic patients had worse survival free of death and hospitalization followed by chagasic and idiopathic compared to other etiologies. Fig. 2Death and hospitalization for all heart failure etiologies. Shows Kaplan Meier curves for all etiologies with death and hospitalization in 12 months

Discussion {#Sec10}
==========

We observed an overall mortality of 6.8% and a composite outcome of death and hospitalization of 17.7% in 1-year of follow-up. It is known that the HF mortality increases with the follow-up time and can reach a median of 40% in 2.5 years \[[@CR13]\]. Our results are in agreement with previous reports. For instance, Maggioni et al. observed all-cause mortality rate at 1 year of 7.2% in chronic stable HF in a pilot study \[[@CR14]\]. In addition, the continuation of this study showed all-cause 1-year mortality rate of 6.4% and combined endpoint of mortality or HF hospitalization within 1 year of 14.5% \[[@CR15]\].

In our cohort, the variables associated with all-cause mortality at 1 year were elevated BUN or log BNP and lower SBP. On the other hand, considering the composite endpoint death and hospitalization, the predictors were age, high sensitive troponin, BNP and BUN. Previous studies have shown a variety of risk predictors \[[@CR13], [@CR16], [@CR17]\] and between then, it is common to find creatinine as representative of renal function and systolic blood pressure. However, although BNP is markedly related to prognosis \[[@CR18], [@CR19]\] it is not present in the best-known risk models \[[@CR13], [@CR16]\]. Due to the fact that studies in chronic heart failure are scarce in the Brazilian population, there are no known critical variables in our population, except in acute patients as in the BREATHE Registry \[[@CR20]\].

The majority of included individuals were in NYHA class I/II (81%) denoting the stable-outpatient character population. Besides, the use of beta-blocker (96.8%) and ACEi or ARB (91%) was high. These facts refer to the good clinical care of the cohort, certainly influencing outcomes.

There was a predominance of hypertensive (26.0%) and ischemic (21.9%) etiologies in our sample, on the other hand, the number of chagasic patients was also important (17.0%). Most studies describe ischemic as the main etiology found in the HF population, however, it depends on study design and ascertainment approaches \[[@CR5]\]. Nonetheless, in our population, Chagas disease is still a major concern. In Brazil, there are endemic areas of Chagas' disease such as the Midwest region \[[@CR21]\] and migration movements can explain this relative high prevalence. Recently, Nadruz et cols evaluated the population attributable risk (PAR) of Chagas cardiomyopathy for 2-year mortality among patients with HF enrolled at years 2002--2004 (era 1) and 2012--2014 (era 2). The era 2 population is part of our cohort and the results found were that although the absolute death rates decreased over time in the Chagas cardiomyopathy and non-Chagas cardiomyopathies groups, the PAR of Chagas cardiomyopathy for mortality increased among patients with HF. Therefore, the current knowledge indicate that of all etiologies, Chagasic HF has the worst prognosis \[[@CR22]\]. In addition, Bernardez-Pereira et al. analyzed the association between genetic ancestry, self-declared race and hemodynamic parameters in the GENIUS-HF cohort and observed a predominance of European ancestry in the entire study population \[[@CR23]\].Taken together, these facts make our cohort *sui generis* and suggest care in the use of risk prediction models from other populations.

The SEATTLE heart failure model was an example of a web-based calculator that estimates 1, 2 and 3-year survival using clinical and pharmacological data easily obtained, but could need calibration in different ethnic populations \[[@CR16]\]. Regardless, many publications on HF risk scores in Europe, North America \[[@CR13], [@CR16], [@CR17]\] and nowadays-in Asian populations \[[@CR6]--[@CR8]\], there is a shortage of studies in the Brazilian population.

We found that patients with ischemic etiology have worse survival free of death and hospitalization in 12 months compared to others etiologies. This is a common observation to many reports and also supports prior community-based epidemiological studies that reported greater risks of coronary heart disease-related deaths \[[@CR24]\].

Limitations {#Sec11}
-----------

This study was specifically designed to study predictors of clinical deterioration in patients with reduced systolic fraction. For this reason we did not perform a subgroup analysis about preserved and mid range fraction patients.

This was a single-center study and, thus, our results might not be applicable to other populations. Nevertheless, the Heart Institute is a nation-wide referral center and our enrolled sample has individuals from different regions of the country.

Conclusions {#Sec12}
===========

High levels of BUN and BNP and low systolic blood pressure were independent predictors of one-year overall mortality in our population. Considering the composite endpoint death and hospitalization, independent predictors were age, high sensitive troponin, BNP and BUN.
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